- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
PCORI Awards $150 Million for Patient-Centered Research
These awards cover research on a variety of crucial health areas including asthma, heart failure, migraine prevention and more.
The Patient-Centered Outcomes Research Institute (PCORI) has awarded over $150 million in funding for new patient-centered comparative clinical effectiveness research (CER) studies. These initiatives cover a variety of crucial health areas including asthma, heart failure, migraine prevention and more.
Nine awards for patient-centered CER have been granted, with two large-scale trials focusing on heart failure and asthma treatments.
In addition, PCORI awarded funds to enhance CER methodologies and gather evidence on how to improve patient engagement in research.
These investments reflect the growing prevalence of patient-centered research in reshaping clinical approaches, as shared in a report by IQVIA.
Reshaping clinical approaches, according to the report, includes building trust and being open in the relationship between patients and researchers.
When patients are included in every part of the research, from planning to analyzing, it creates a sense of respect on both sides. This not only keeps people engaged but also supplies researchers with crucial data.
Showcasing a wide range of data sources, patient-centered research goes beyond traditional clinical outcomes to include the experiences and preferences of patients, according to the report.
In return, this approach results in the credibility of research findings.
As patient-centered research continues to grow, it marks a significant shift in healthcare toward a model where the patient's perspective supports scientific exploration and ensures that research outcomes benefit who they are meant to.
“As a leading funder of patient-centered comparative clinical effectiveness research, PCORI recognizes the evidence generated from PCORI-funded research helps patients and those who care for them make informed decisions about which health care options will work best for them," PCORI executive sirector Nakela L. Cook, M.D., MPH, said in the release.
Trust, transparency and the utilization of high-quality data is crucial to develop deeper insights and more impactful healthcare solutions.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
The Relationship Between ILD and MDA5 Antibody-Positive DM
May 2nd 2024Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.
Read More
